Hepato-protective effect of polaprezinc for patients with autoimmune hepatitis

Hepato-protective effect of polaprezinc for patients with autoimmune hepatitis - Hepato-protective effect of polaprezinc

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022959

Enrollment

100

Registered

2016-06-30

Start date

2016-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune hepatitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients obtained written informed consent 2) Patients with peptic ulcer 3) Patients with autoimmune hepatitis

Exclusion criteria

Exclusion criteria: 1) Patients with oral intake difficulty 2) Patients with severe digestive disease 3) Pregnant woman, lactating woman, or a woman suspected of pregnancy 4) Patients with severe allergic reaction 5) Patients with drug abuse or psycological disorders

Design outcomes

Primary

Measure	Time frame
Improvement of hepatic functional reserve after continuous intake of polaprezinc	—

Secondary

Measure	Time frame
Improvement of hepatic fibrosis marker	—

Countries

Japan

Contacts

Public ContactKEI MORIYA

Nara Medical University Third Department of Internal Medicine

moriyak@naramed-u.ac.jp0744-22-3051

Outcome results